Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: August 21, 2017
What is the competitive landscape for PFIZER, and what generic alternatives to PFIZER drugs are available?
PFIZER has one hundred and fifty-five approved drugs.| Patents: | 58 |
| Tradenames: | 122 |
| Ingredients: | 107 |
| NDAs: | 155 |
| Drug Master File Entries: (click here to view) | 3 |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | GEODON | ziprasidone hydrochloride | CAPSULE;ORAL | 020825-003 | Feb 5, 2001 | AB | RX | Yes | No | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
Pfizer | ZOLOFT | sertraline hydrochloride | CONCENTRATE;ORAL | 020990-001 | Dec 7, 1999 | AA | RX | Yes | Yes | ► Subscribe | ► Subscribe | Y | ► Subscribe | ||||||||||||||||
Pfizer | STREPTOMYCIN SULFATE | streptomycin sulfate | INJECTABLE;INJECTION | 060076-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
Pfizer | STREPTOMYCIN SULFATE | streptomycin sulfate | INJECTABLE;INJECTION | 060076-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
Pfizer | SPECTROBID | bacampicillin hydrochloride | TABLET;ORAL | 050520-002 | Sep 12, 1983 | DISCN | No | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | CARDURA | doxazosin mesylate | TABLET;ORAL | 019668-002 | Nov 2, 1990 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Pfizer Pharms | ACCUPRIL | quinapril hydrochloride | TABLET;ORAL | 019885-004 | Nov 19, 1991 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Pfizer | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-004 | Apr 7, 2000 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Pfizer | CADUET | amlodipine besylate; atorvastatin calcium | TABLET;ORAL | 021540-001 | Jan 30, 2004 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Pfizer | CADUET | amlodipine besylate; atorvastatin calcium | TABLET;ORAL | 021540-004 | Jan 30, 2004 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
tofacitinib | Extended-release Tablets | 11 mg | XELJANZ XR | 11/7/2016 |
ibuprofen and diphenhydramine citrate | Capsules | 200 mg/38 mg | ADVIL PM | 2/16/2016 |
dofetilide | Capsules | 0.125 mg, 0.25 mg, and 0.5 mg | TIKOSYN | 5/1/2014 |
fesoterodine fumarate | Extended-release Tablets | 4 mg and 8 mg | TOVIAZ | 10/31/2012 |
nitroglycerin | Sublingual Tablets | 0.6 mg | NITROSTAT | 12/29/2011 |
azithromycin | For Injection | 500 mg/vial | ZITHROMAX | 6/17/2011 |
varenicline tartrate | Tablets | 0.5 mg and 1 mg | CHANTIX | 5/10/2010 |
eletriptan hydrobromide | Tablets | 20 mg and 40 mg | RELPAX | 3/29/2010 |
amlodipine besylate and atorvastatin calcium | Tablets | 2.5 mg/40 mg | CADUET | 9/17/2009 |
amlodipine besylate and atorvastatin calcium | Tablets | 5 mg/80 mg | CADUET | 4/7/2009 |
amlodipine besylate and atorvastatin calcium | Tablets | 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/10 mg, 10 mg/20 mg and 10 mg/80 mg | CADUET | 12/29/2006 |
sertraline hydrochloride | Tablets | 150 mg and 200 mg | ZOLOFT | 11/9/2005 |
nitroglycerin | Sublingual Tablets | 0.3 mg, 0.4 mg and 0.6 mg | NITROSTAT | 10/19/2005 |
zaleplon | Capsules | 5 mg and 10 mg | SONATA | 6/21/2005 |
ziprasidone hydrochloride | Capsules | 20 mg, 40 mg, 60 mg and 80 mg | GEODON | 2/7/2005 |
ibuprofen potassium and pseudoephedrine hydrochloride | Capsules | 200 mg/30 mg | ADVIL COLD AND SINUS | 12/27/2004 |
sildenafil citrate | Tablets | 25 mg and 50 mg | VIAGRA | 11/19/2004 |
sildenafil citrate | Tablets | 100 mg | VIAGRA | 10/25/2004 |
irinotecan hydrochloride | Injection | 20 mg/mL, 2 mL and 5 mL vials | CAMPTOSAR | 7/26/2004 |
| Patent Number | Expiration Date |
|---|---|
| ► Subscribe | ► Subscribe |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7,422,013 | Dry powder dispersing apparatus and methods for their use | ► Subscribe | |||||||||||||||||||||||||||
| 8,685,444 | Sequestering subunit and related compositions and methods | ► Subscribe | |||||||||||||||||||||||||||
| 8,883,217 | Modified release formulations containing drug-ion exchange resin complexes | ► Subscribe | |||||||||||||||||||||||||||
| 6,361,795 | Method for lowering blood glucose | ► Subscribe | |||||||||||||||||||||||||||
| 8,449,876 | Human lysosomal proteins from plant cell culture | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Slovakia | 4582001 | ► Subscribe | |||||||||||||||||||||||||||
| South Africa | 200307235 | ► Subscribe | |||||||||||||||||||||||||||
| Spain | 2218543 | ► Subscribe | |||||||||||||||||||||||||||
| Hungary | 9301098 | ► Subscribe | |||||||||||||||||||||||||||
| European Patent Office | 2018160 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C/GB97/010 | United Kingdom | ► Subscribe | PRODUCT NAME: GENERIC NAME: IRINOTECANCHEMICAL NAME: (+)-(4S)-4,11-DIETHYL-4-HYDROXY-9-((4-PIPERIDINOPIPERIDINO)CARBONYLOXY)-1H-PYRANO (3',4':6,7) INDOLIZINO(1,2-B) QUINOLINE-3,14-(4H,12H)-DIONE,OPTIONALLY THE HYDROCHLORIDE SALT THEREOF AND OPTIONALLY THE TRIHYDRATE T; REGISTERED: FR 558822.2 19950505; FR 558823.9 19950505; FR 558824.5 19950505; FR 558825.1 19950505; UK 00012/0302 19961017; UK 00012/0303 19961017 | ||||||||||||||||||||||||||
| 315 | Luxembourg | ► Subscribe | PRODUCT NAME: COMBINAISON COMPRENANT ALISKIREN,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE,ET AMLODIPINE,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE | ||||||||||||||||||||||||||
| 80045 | Netherlands | ► Subscribe | PRODUCT NAME: FOSPHENYTOINUM-DI-NATRICUM; NATL REGISTRATION NO/DATE: RVG 22758 19980702; FIRST REGISTRATION: GB PL 00019/0157 19980204 | ||||||||||||||||||||||||||
| C/GB08/005 | United Kingdom | ► Subscribe | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022. | ||||||||||||||||||||||||||
| C0040 | Belgium | ► Subscribe | PRODUCT NAME: ALATROFLOXACIN; NAT. REGISTRATION NO/DATE: EU/1/98/060/001 19980327; FIRST REGISTRATION: CH 54484 19980327 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,367 others who get our Drug Patent Expiration Alerts:
